// App-Quantinova.ai

: CASEIN KINASE II INHIBITION SENSITIZES ACUTE LYMPHOBLASTIC LEUKEMIA CELLS TO VENETOCLAX VIA MCL-1 DEGRADATION

Researchers

Presenter

  • Juan Lazaro-Navarro

Principal Investigators

  • Helia Judith Pimentel-Gutirrez

  • Binje Vick

  • Jassi Eisenschmid

  • Irmela Jeremias

  • Martin Neumann

  • Sonja Hnzelmann

  • Nicola Gkbuget

  • Hubert Serve

  • Michael Rieger

  • Cornelia Eckert

  • Claudia Baldus

  • Lorenz Bastian

Medical Centers

  • German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany;Department of Pediatrics, Division of Oncology and Hematology.,Charité – Universitätsmedizin Berlin,Berlin,Germany

  • Department of Pediatric Oncology and Hematology,Charite - Universitaetsmedizin,Berlin,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany

  • Department of Apoptosis in Hematopoietic Stem Cells,Helmholtz Center Munich,Munich,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany

  • Department of Medicine, Hematology/Oncology,Goethe University Hospital Frankfurt,Frankfurt,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany

  • Department of Hematology/Oncology,Universitätsklinikum Schleswig- Holstein,Kiel,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • Casein

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved